Moderna (MRNA) Other Non Operating Income (2018 - 2026)

Moderna (MRNA) has 9 years of Other Non Operating Income data on file, last reported at -$18.0 million in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 350.0% year-over-year to -$18.0 million in Q1 2026; TTM through Mar 2026 was -$22.0 million, a 69.44% increase from a year earlier, with the FY2025 full-year figure at -$8.0 million, up 90.8% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$18.0 million, down from -$12.0 million in the prior quarter.
• Over the last five years, Other Non Operating Income for MRNA reached as high as $14.0 million in Q2 2023 and fell as low as -$51.0 million in Q3 2023.
• Historically, Other Non Operating Income has averaged -$17.6 million across 5 years, with a median of -$13.0 million in 2022.
• On a YoY basis, Other Non Operating Income climbed as much as 207.69% in 2023 and fell as far as 628.57% in 2023.
• Year by year, Other Non Operating Income stood at -$12.0 million in 2022, then sank by 225.0% to -$39.0 million in 2023, then gained by 25.64% to -$29.0 million in 2024, then soared by 58.62% to -$12.0 million in 2025, then slumped by 50.0% to -$18.0 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were -$18.0 million in Q1 2026, -$12.0 million in Q4 2025, and $8.0 million in Q2 2025.